Sacubitril sodium
| Code | Size | Price |
|---|
| TAR-T4574L-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4574L-50mg | 50mg | £1,661.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T4574L-100mg | 100mg | £2,079.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Sacubitril is an angiotensin receptor neprilysin inhibitor being studied for use in combination with valsartan for heart failure. Sacubitril is a prodrug that is activated to LBQ657 by de-ethylation via esterases.
CAS:
149690-05-1
Formula:
C24H28NNaO5
Molecular Weight:
433.48
Purity:
0.98
SMILES:
[Na+].CCOC(=O)C(C)CC(Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC([O-])=O
References
B?hm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJ. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 Feb 1. doi: 10.1093/eurheartj/ehw570. [Epub ahead of print] PubMed PMID: 28158398.
Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q, Guo W. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017 Mar;69(3):411-420. doi: 10.1161/HYPERTENSIONAHA.116.08556. PubMed PMID: 28093466.
Kaplinsky E. Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination. J Geriatr Cardiol. 2016 Nov;13(11):914-923. doi: 10.11909/j.issn.1671-5411.2016.11.006. Review. PubMed PMID: 28133468; PubMed Central PMCID: PMC5253408.
Fox H, Bitter T, Horstkotte D, Oldenburg O. Resolution of Cheyne-Stokes Respiration after Treatment of Heart Failure with Sacubitril/Valsartan: A First Case Report. Cardiology. 2017 Feb 9;137(2):96-99. doi: 10.1159/000455118. [Epub ahead of print] PubMed PMID: 28178694.